The following is a summary of “Efficacy and safety of gefapixant in women with chronic cough and cough-induced stress urinary incontinence: a phase 3b, randomised, multicentre, double-blind, ...

An international clinical trial to test the first new cough drug in 50 years is being led by The University of Manchester’s Professor Jaclyn Smith. If approved, the promising new treatment could offer ...

BOSTON & SEATTLE--(BUSINESS WIRE)--Sensory Cloud Inc., a health technology company pioneering treatments ... reduced cough frequency in patients suffering from refractory chronic cough (RCC).

Appropriate treatment for these factors resulted in a significant improvement in cough. Conclusion: Reflux, allergy, and asthma accounted for > 80% of the likely etiologic factors of chronic cough ...

If the patient has clinical symptoms, then treatment is acid suppressive therapy for 4-8 weeks, followed by a clinical reassessment. An uncommon cause of chronic cough with no biological mechanism ...

NEW HAVEN, Conn., Oct. 21, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral ...

Phase 2a Trial Design: Refractory Chronic Cough Improvement Via Nal ER (RIVER) The Phase 2a RIVER trial is a randomized, double-blind, placebo-controlled, two-treatment, two-period, crossover ...